Hetero-bicyclic derivatives as HCV inhibitors

1. A compound of Formula I

or a stereoisomer thereof, wherein:

each

 independently is pyrrolidin-2-yl, 2-aza-bicyclo[3.1.0]hexan-3-yl, piperidin-2-yl, 2-aza-bicyclo[2.2.1]hept-2-yl or octahydro-1H-indol-2-yl wherein each of said heterocycles may optionally be substituted by one or more halogen atoms;

Z C Y is CR 4 =C—NH, NH—C=CH or NH—C=N;

X 1 is CH and X 2 is CH; or

X 1 is CH and X 2 is N; or

X 1 is N and X 2 is CH;

W is carbonyl, sulfonyl or CR 5 R 6 ;

R and R′ are independently selected from —CR 1 R 2 R 3 , aryl optionally substituted with 1 or 2 substituents selected from halo and methyl, or heterocycloalkyl, wherein

R 1 is selected from C 1-4 alkyl optionally substituted with methoxy, hydroxyl or dimethylamino; C 3-6 cycloalkyl; tetrahydropyranyl; phenyl optionally substituted with 1, 2 or 3 substituents independently selected from halo, C 1-4 alkoxy, trifluoromethoxy or 2 substituents on adjacent ring atoms form a 1,3-dioxolane group; benzyl optionally substituted with halo or methoxy; heteroaryl; and heteroarylmethyl;

R 2 is selected from hydrogen, hydroxyl, amino, mono- or di-C 1-4 alkylamino, (C 3-6 cycloalkyl)(C 1-4 alkyl)amino, C 1-4 alkylcarbonylamino, phenylamino, C 1-4 alkyloxycarbonylamino, (C 1-4 alkyloxycarbonyl)(C 1-4 alkyl)amino, C 1-4 alkylaminocarbonylamino, tetrahydro-2-oxo-1(2H)-pyrimidinyl, pyrrolidin-1-yl, piperidin-1-yl, 3,3-difluoropiperidin-1-yl, morpholin-1-yl, 7-azabicyclo[2.2.1]hept-7-yl, and imidazol-1-yl; and

R 3 is hydrogen or C 1-4 alkyl, or

CR 2 R 3 together forms carbonyl; or

CR 1 R 3 forms a cyclopropyl group;

R 4 is hydrogen, C 1-4 alkyl or cyano;

R 5 and R 6 , each independently, are C 1-4 alkyl; or

CR 5 R 6 together form C 3-7 cycloalkyl, oxetane, tetrahydrofurane;

or a pharmaceutically acceptable salts or a solvate thereof.

2. The compound of claim 1 , wherein each each

independently is pyrrolidin-2-yl, 2-aza-bicyclo[3.1.0]hexan-3-yl or piperidin-2-yl.

3. The compound of claim 1 , wherein each

independently is pyrrolidin-2-yl or 2-aza-bicyclo[3.1.0]hexan-3-yl, wherein each of said heterocycles may optionally be substituted by one or more halogen atoms.

4. The compound of claim 1 , wherein Z C Y is CH═C—NH.

5. The compound of claim 1 , wherein R and R′ are the same.

6. The compound of claim 1 , wherein R 2 is hydroxyl, amino, mono- or di-C 1-4 alkylamino, C 1-4 alkyl- carbonylamino, C 1-4 alkyloxy-carbonylamino.

7. The compound of claim 1 , wherein R 1 is selected from C 1-4 alkyl; C 2-4 alkyl substituted with methoxy or hydroxyl; phenyl; and phenyl substituted with 1 or 2 substituents independently selected from halo and methyl.

8. The compound of claim 1 , which is

9. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

10. A product containing (a) a compound of claim 1 , and (b) another HCV inhibitor, as a combined preparation for simultaneous, separate or sequential use in the treatment of HCV infections.

11. A method for the treatment of an HCV infection comprising administering the pharmaceutical composition of claim 9 to a patient in need thereof.